|Table of Contents|

Neoadjuvant therapy for triple negative breast cancer：Clinical progress

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
566-571
Research Field:
Publishing date:

Info

Title:
Neoadjuvant therapy for triple negative breast cancer：Clinical progress
Author(s):
CHEN Anli1; SHEN Haoyuan2; WANG Shu1
1.Jinzhou Medical University,Liaoning Jinzhou 121000,China;2.Affiliated Hospital of Wuhan University of Science and Technology (Xiaogan Central Hospital),Hubei Xiaogan 432100,China.
Keywords:
triple negative breast cancer; neoadjuvant therapy; pathological complete response; platinum; PARP inhibitors; immune checkpoint inhibitors
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.03.035
Abstract:
Triple negative breast cancer (TNBC) is a kind of invasive breast cancer,the prognosis is poor due to the lack of effective targeted therapy.Neoadjuvant therapy for breast cancer has become an important treatment strategy for TNBC,because it can increase the probability of breast and axillary preservation in the health period,and can also screen high-risk groups to obtain drug-sensitive information to guide subsequent drug use.In this review,the latest advances in neoadjuvant therapy for TNBC are reviewed,including targeted therapy of tumor microenvironment (TME) by the platinum-based immunosuppressant PARP inhibitor phosphatidlinositol-4,5-diphosphate 3 kinase catalytic subunit (PIK3CA) pathway.

References:

［1］BILLAR JA,DUECK AC,STUCKY CC,et al.Triple-negative breast cancers:unique clinical presentations and outcomes［J］.Ann Surg Oncol,2010,17(Suppl 3):384-390.
［2］MALORNI L,SHETTY PB,DE ANGELIS C,et al.Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up［J］.Breast Cancer Res Treat,2012,136(3):795-804.
［3］LI X,YANG J,PENG L,et al.Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer［J］.Breast Cancer Res Treat,2017,161(2):279-287.
［4］MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics［J］.CA Cancer J Clin,2019,69(5):363-385.
［5］YIN L,DUAN JJ,BIAN XW,et al.Triple-negative breast cancer molecular subtyping and treatment progress［J］.Breast Cancer Res,2020,22(1):61.
［6］GARRIDO-CASTRO AC,LIN NU,POLYAK K.Insights into molecular classifications of triple-negative breast cancer:Improving patient selection for treatment［J］.Cancer Discov,2019,9(2):176-198.
［7］BROGLIO KR,QUINTANA M,FOSTER M,et al.Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes:A Meta-analysis［J］.JAMA Oncol,2016,2(6):751-760.
［8］KOZAK MM,JACOBSON CE,VON EYBEN R,et al.Outcomes following neoadjuvant chemotherapy for breast cancer in women aged 40 years and younger:Impact of pathologic nodal response［J］.J Natl Compr Canc Netw,2018,16(7):845-850.
［9］CORTAZAR P,ZHANG L,UNTCH M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis［J］.Lancet,2014,384(9938):164-172.
［10］VON MINCKWITZ G,UNTCH M,BLOHMER JU,et al.Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］.J Clin Oncol,2012,30(15):1796-1804.
［11］BISWAS T,EFIRD JT,PRASAD S,et al.The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer［J］.Oncotarget,2017,8(68):112712-112719.
［12］CHEN VE,GILLESPIE EF,ZAKERI K,et al.Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer［J］.Adv Radiat Oncol,2017,2(2):105-109.
［13］GAMUCCI T,PIZZUTI L,SPERDUTI I,et al.Neoadjuvant chemotherapy in triple-negative breast cancer:A multicentric retrospective observational study in real-life setting［J］.J Cell Physiol,2018,233(3):2313-2323.
［14］LEHMANN BD,BAUER JA,CHEN X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies［J］.J Clin Invest,2011,121(7):2750-2767.
［15］LEHMANN BD,JOVANOVIC B,CHEN X,et al.Refinement of triple-negative breast cancer molecular subtypes:Implications for neoadjuvant chemotherapy selection［J］.PLoS One,2016,11(6):e0157368.
［16］JIANG YZ,MA D,SUO C,et al.Genomic and transcriptomic landscape of triple-negative breast cancers:Subtypes and treatment strategies［J］.Cancer Cell,2019,35(3):428-440.e5.
［17］GARUTTI M,PELIZZARI G,BARTOLETTI M,et al.Platinum salts in patients with breast cancer:A focus on predictive factors［J］.Int J Mol Sci,2019,20(14):3390.
［18］BYRSKI T,GRONWALD J,HUZARSKI T,et al.Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy［J］.J Clin Oncol,2010,28(3):375-379.
［19］ISAKOFF SJ,MAYER EL,HE L,et al.TBCRC009:A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer［J］.J Clin Oncol,2015,33(17):1902-1909.
［20］BYRSKI T,GRONWALD J,HUZARSKI T,et al.Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy［J］.J Clin Oncol,2010,28(3):375-379.
［21］SIKOV WM,BERRY DA,PEROU CM,et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer:CALGB 40603 (Alliance)［J］.J Clin Oncol,2015,33(1):13-21.
［22］VON MINCKWITZ G,SCHNEEWEISS A,LOIBL S,et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66):a randomised phase 2 trial［J］.Lancet Oncol,2014,15(7):747-756.
［23］POGGIO F,BRUZZONE M,CEPPI M,et al.Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer:a systematic review and meta-analysis［J］.Ann Oncol,2018,29(7):1497-1508.
［24］LOIBL S,O'SHAUGHNESSY J,UNTCH M,et al.Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess):a randomised,phase 3 trial［J］.Lancet Oncol,2018,19(4):497-509.
［25］FILHO OM,STOVER DG,ASAD S,et al.Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer:A secondary analysis of the BrighTNess Phase 3 Randomized Clinical Trial［J］.JAMA Oncol,2021,18:e207310.
［26］SCHMID P,CORTES J,PUSZTAI L,et al.Pembrolizumab for early triple-negative breast cancer［J］.N Engl J Med,2020,382(9):810-821.
［27］HUANG L,LIU Q,CHEN S,et al.Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer［J］.Onco Targets Ther,2017,10:5739-5744.
［28］UNTCH M,JACKISCH C,SCHNEEWEISS A,et al.NAB-paclitaxel improves disease-free survival in early breast cancer:GBG 69-GeparSepto［J］.J Clin Oncol,2019,37(25):2226-2234.
［29］SULAI NH,TAN AR.Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer［J］.Clin Adv Hematol Oncol,2018,16(7):491-501.
［30］HAN Y,YU X,LI S,et al.New perspectives for resistance to PARP inhibitors in triple-negative breast cancer［J］.Front Oncol,2020,10:578095.
［31］ROBSON M,IM SA,SENKUS E,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation［J］.N Engl J Med,2017,377(6):523-533.
［32］LITTON JK,RUGO HS,ETTL J,et al.Talazoparib in patients with advanced breast cancer and a germline BRCA mutation［J］.N Engl J Med,2018,379(8):753-763.
［33］LITTON JK,SCOGGINS ME,HESS KR,et al.Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant［J］.J Clin Oncol,2020,38(5):388-394.
［34］RUGO HS,OLOPADE OI,DEMICHELE A,et al.Adaptive randomization of veliparib-carboplatin treatment in breast cancer［J］.N Engl J Med,2016,375(1):23-34.
［35］FASCHING PA,LINK T,HAUKE J,et al.Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)［J］.Ann Oncol,2021,32(1):49-57.
［36］KWA MJ,ADAMS S.Checkpoint inhibitors in triple-negative breast cancer (TNBC):Where to go from here［J］.Cancer,2018,124(10):2086-2103.
［37］ASANO Y,KASHIWAGI S,GOTO W,et al.Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression［J］.J Transl Med,2018,16(1):87.
［38］LIU Z,LI M,JIANG Z,et al.A comprehensive immunologic portrait of triple-negative breast cancer［J］.Transl Oncol,2018,11(2):311-329.
［39］MITTENDORF EA,ZHANG H,BARRIOS CH,et al.Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031):a randomised,double-blind,phase 3 trial［J］.Lancet,2020,396(10257):1090-1100.
［40］DENKERT C,VON MINCKWITZ G,DARB-ESFAHANI S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy［J］.Lancet Oncol,2018,19(1):40-50.
［41］LO RUSSO PM.Inhibition of the PI3K/AKT/mTOR pathway in solid tumors［J］.J Clin Oncol,2016,34(31):3803-3815.
［42］GHAYAD SE,COHEN PA.Inhibitors of the PI3K/Akt/mTOR pathway:new hope for breast cancer patients［J］.Recent Pat Anticancer Drug Discov,2010,5(1):29-57.
［43］OLIVEIRA M,SAURA C,NUCIFORO P,et al.FAIRLANE,a doubleblind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer［J］.Ann Oncol,2019,30(8):1289-1297.
［44］NIEMEIER LA,DABBS DJ,BERIWAL S,et al.Androgen receptor in breast cancer:expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation［J］.Mod Pathol,2010,23(2):205-212.
［45］PARK S,KOO J,PARK HS,et al.Expression of androgen receptors in primary breast cancer［J］.Ann Oncol,2010,21(3):488-492.
［46］DEEPAK KGK,VEMPATI R,NAGARAJU GP,et al.Tumor microenvironment:Challenges and opportunities in targeting metastasis of triple negative breast cancer［J］.Pharmacol Res,2020,153:104683.

Memo

Memo:
湖北省卫生健康委员会联合基金（编号：WJ2019H246）
Last Update: 1900-01-01